| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.11. | Summit sheds commercial leaders ahead of ivonescimab's FDA decision | ||
| 10.11. | J&J readies Caplyta for FDA label expansion after 2nd phase 3 win in bipolar mania | ||
| 10.11. | After court win, WuXi AppTec scores removal from US list of Chinese military companies | ||
| 10.11. | FDA orders new eye risk be listed on a dozen GLP-1s, including Novo's Ozempic, Lilly's Zepbound | ||
| 10.11. | Phillips Medisize strikes deal to expand UK inhalation production | ||
| 10.11. | Vertex lays off 78 Crinetics staffers amid $10B integration | ||
| 10.11. | Insulet, Marvel Comics smash diabetes stigma with new Omnipod-powered superhero | ||
| 10.11. | Bayer brings factor XIa to US stroke prevention with FDA nod for 1st-in-class asundexian | ||
| 09.11. | Veradermics wraps phase 3 program in men with 'better-than-expected' hair growth at 1 year | ||
| 09.11. | FDA opens safety probe into Novartis' Zolgensma over potential tumor risks | ||
| 09.11. | J&J's Icotyde pill drives biologic-like efficacy in psoriatic arthritis despite high-dose miss | ||
| 09.11. | Lilly looks to gird Foundayo label after late-stage win in sleep apnea | ||
| 09.11. | Moderna moves UK commercial digs to heart of London's 'knowledge quarter' | ||
| 09.11. | Agentic AI Is Rewriting The Pharma Marketing Playbook | ||
| 09.11. | Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care | ||
| 06.11. | Actor Jeremy Pope joins ViiV's 'PrEP Wisdom' campaign to educate on long-acting PrEP options | ||
| 06.11. | Moderna's COVID vaccine carries stellar Q3 revenue beat | ||
| 06.11. | Fierce Pharma Asia-Boehringer's $7.4B SBP deal; Fresenius' sweeping biosim pact; A $1B molecular glue bet | ||
| 06.11. | Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details | ||
| 05.11. | ANI makes $560M play for Egetis and its approved orphan drug Emcitate | ||
| 05.11. | RevMed's Rasonque debut nets 'eye-popping' $198M in 5 weeks, even as exec tempers expectations | ||
| 05.11. | Boehringer Ingelheim brings liver health education push to the NASCAR fast lane | ||
| 05.11. | AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war | ||
| 05.11. | VintaBio assets go on auction block as CGT viral vector demand slows | ||
| 05.11. | Alnylam seeks new commercial leader as Tolga Tanguler exits amid faltering Amvuttra trajectory |